Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Researchers achieve long-term remission with novel T cell therapies for HPV-related cancers

10

Nov 2025

Researchers achieve long-term remission with novel T cell therapies for HPV-related cancers

Researchers from Rutgers Cancer Institute, New Jersey's only National Cancer Institute (NCI) - designated Comprehensive Cancer Center, and RWJBarnabas Health, along with colleagues from the National Cancer Institute, a center of the National Institutes of Health, announced findings from two HPV-related studies that highlight the potential of novel T cell therapies to achieve long-lasting remission and complete tumor regression in patients with advanced epithelial cancers.

Study uncovers new mechanism for chromosome congression during mitosis

10

Nov 2025

Study uncovers new mechanism for chromosome congression during mitosis

A research team from The University of Osaka, in collaboration with the Massachusetts Institute of Technology, has uncovered a new molecular mechanism underlying chromosome alignment during cell division. The study demonstrates that two motor proteins, KIF18A and CENP-E, act cooperatively to ensure proper chromosome congression. Remarkably, simultaneous inhibition of these proteins selectively kills cancer cells, suggesting a promising therapeutic avenue.

Comparative study finds higher rates of adverse events with ticagrelor

10

Nov 2025

Comparative study finds higher rates of adverse events with ticagrelor

One year of treatment with either of two strong blood-thinning medications—ticagrelor and prasugrel—by people with type 1 or type 2 diabetes who had a drug-eluting stent placed in their heart to treat coronary artery blockages did not offer the same level of benefit to prevent stent clotting, heart attacks, and bleeding complications, according to findings presented during a preliminary late-breaking science session during the American Heart Association's Scientific Sessions 2025 in New Orleans on November 10.

Green-synthesized nanoparticles enhance cidofovir's anticancer efficacy

10

Nov 2025

Green-synthesized nanoparticles enhance cidofovir's anticancer efficacy

In this study, led by Nahid Shahabadi from Razi University in Kermanshah, researchers developed an environmentally friendly approach to enhance the performance of cidofovir, a drug used to treat infections caused by DNA viruses. The work responds to the growing need for therapies that are safer, more effective, and better targeted.

Clinical trial confirms ivermectin safety in very young children down to 5 kg

10

Nov 2025

Clinical trial confirms ivermectin safety in very young children down to 5 kg

Millions of very young children currently excluded from treatment with the drug ivermectin could be safely included in ongoing campaigns against challenging and often neglected tropical diseases such as intestinal worms, scabies and river blindness, according to results from a clinical trial presented today at the Annual Meeting of the American Society of Tropical Medicine and Hygiene (ASTMH).

Micro-RNA in sperm proves vital for human embryogenesis

10

Nov 2025

Micro-RNA in sperm proves vital for human embryogenesis

The sperm is not a passive supplier of genetic material to the egg. A study from Linköping University, Sweden, shows that certain molecules that come with the sperm, so-called micro-RNA, contribute to the development of the embryo several days after conception. The findings, published in the journal Nature Communications, may in the long term contribute to better diagnosis and treatment of involuntary childlessness.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.